New Insights into the Effects of Etelcalcetide on Bone Health.
作者信息
Ginsberg Charles, Ix Joachim H
机构信息
Division of Nephrology-Hypertension, University of California, San Diego, San Diego, California.
Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California.
出版信息
Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1388-1390. doi: 10.2215/CJN.0000000000000316. Epub 2023 Oct 3.
Abstract
摘要
相似文献
1
New Insights into the Effects of Etelcalcetide on Bone Health.
Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1388-1390. doi: 10.2215/CJN.0000000000000316. Epub 2023 Oct 3.
2
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468.
3
Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Am J Kidney Dis. 2020 Sep;76(3):321-330. doi: 10.1053/j.ajkd.2020.02.439. Epub 2020 May 28.
4
Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes.
Hemodial Int. 2022 Apr;26(2):243-254. doi: 10.1111/hdi.12996. Epub 2021 Dec 20.
5
Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
J Am Soc Nephrol. 2022 Jan;33(1):201-212. doi: 10.1681/ASN.2021060825. Epub 2021 Nov 3.
6
Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis.
Eur J Clin Pharmacol. 2024 Oct;80(10):1555-1569. doi: 10.1007/s00228-024-03730-5. Epub 2024 Jul 13.
7
Etelcalcetide for the treatment of secondary hyperparathyroidism.
Expert Opin Pharmacother. 2017 Apr;18(5):529-534. doi: 10.1080/14656566.2017.1303482. Epub 2017 Mar 15.
8
Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
Semin Dial. 2018 Sep;31(5):440-444. doi: 10.1111/sdi.12734. Epub 2018 Jul 15.
9
Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study.
J Int Med Res. 2018 Nov;46(11):4578-4585. doi: 10.1177/0300060518786913. Epub 2018 Jul 20.
10
Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Curr Osteoporos Rep. 2023 Apr;21(2):193-204. doi: 10.1007/s11914-023-00782-x. Epub 2023 Feb 27.
本文引用的文献
1
Changes in Bone Quality after Treatment with Etelcalcetide.
Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1456-1465. doi: 10.2215/CJN.0000000000000254. Epub 2023 Aug 14.
2
Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013-2017.
Am J Nephrol. 2021;52(12):919-928. doi: 10.1159/000520028. Epub 2021 Nov 23.
3
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456.
4
Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.
Am J Kidney Dis. 2016 Apr;67(4):559-66. doi: 10.1053/j.ajkd.2015.06.023. Epub 2015 Aug 25.
5
Rapid cortical bone loss in patients with chronic kidney disease.
J Bone Miner Res. 2013 Aug;28(8):1811-20. doi: 10.1002/jbmr.1916.
6
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.
7
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
Kidney Int. 2005 Oct;68(4):1793-800. doi: 10.1111/j.1523-1755.2005.00596.x.
8
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
J Am Soc Nephrol. 2005 Mar;16(3):800-7. doi: 10.1681/ASN.2004060512. Epub 2005 Feb 2.
9
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
J Am Soc Nephrol. 2004 Aug;15(8):2208-18. doi: 10.1097/01.ASN.0000133041.27682.A2.
10
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
N Engl J Med. 2004 Apr 8;350(15):1516-25. doi: 10.1056/NEJMoa031633.
Zotero 插件